Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Introducing Violet(TM) Iodine, New Once-Daily, Non-Prescription Pill For Relief Of Premenstrual Breast Discomfort*

Formulated to Help Alleviate Symptoms Associated with Fibrocystic Breast Condition for the Estimated 50 Percent of Women Aged 15 to 49 Who Suffer from Monthly Breast Discomfort


News provided by

BioPharmX Corporation

Dec 09, 2014, 05:20 ET

Share this article

Share toX

Share this article

Share toX

MENLO PARK, Calif., Dec. 9, 2014 /PRNewswire/ -- BioPharmX Corporation (OTCQB: BPMX) today announced the availability of VioletTM iodine, a new, once-daily pill for relief of premenstrual breast discomfort. The first-of-its-kind product is based on the latest molecular iodine technology designed to help free women from the burden of breast discomfort by addressing the underlying causes of a condition known as fibrocystic breast condition (FBC), with the added benefit of promoting breast health for women of reproductive age.*

Continue Reading
Introducing Violet(TM) iodine to help relieve premenstrual breast discomfort (PRNewsFoto/BioPharmX Corporation) (PRNewsFoto/BioPharmX Corporation)
Introducing Violet(TM) iodine to help relieve premenstrual breast discomfort (PRNewsFoto/BioPharmX Corporation) (PRNewsFoto/BioPharmX Corporation)

To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/7378951-biopharmx-introducing-violet-iodine-premenstrual-breast-discomfort

"Fibrocystic breast condition is the generally accepted term to describe a common, benign condition that is associated with varying levels of monthly breast discomfort, including breast tenderness, aches, swelling, and heaviness," said Dr. Lisa Masterson, OBGYN. "FBC affects an estimated 50 percent of women between the ages of 15-49,1 or over 35 million women in America, which is why I am thrilled there is now an option for my patients and the many women living with this condition to manage their discomfort."

Fibrocystic breast condition is thought to be caused by hormonal imbalances, which can cause breast tissue growth to exceed its natural cell turnover. Breast tissue builds up month after month with each menstrual cycle, resulting in swollen, achy and tender breasts. 

Daily use of Violet iodine can help normalize these imbalances and address the underlying causes of fibrocystic breast condition, thereby alleviating symptoms that vary in severity from general soreness to clinically diagnosed FBC.* One clinical study showed that women taking a daily dose of either 3 or 6 mg of iodine showed a decrease in monthly breast discomfort relative to women taking a daily dose of either a placebo or 1.5 mg of iodine.1*

"What is unique about Violet iodine is its non-hormonal formula of patented molecular iodine, which aims to target the breast tissue with limited introduction in the thyroid,"* said Dr. Lee P. Shulman, Professor and Head of the Section of Reproductive Genetics in the Department of Obstetrics and Gynecology at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois. "Adding Violet iodine to a woman's daily regimen can help safely relieve the most common forms of breast pain and discomfort, including aches and swelling, while also maintaining healthy breast tissue."*

When taken daily, Violet iodine can begin to provide relief of symptoms after several months or approximately two menstrual cycles, though some women see relief much sooner.* Beyond FBC, Violet iodine can support women through breast tissue changes over the course of their lives by maintaining healthy cell growth – from onset of menstruation to menopause.* Daily consumption of iodine is typically safe for most people.

"Discomfort from monthly breast pain associated with fibrocystic breast condition can impact a woman's lifestyle, from restricting the types of clothes she wears and limiting her ability to exercise regularly to preventing her from hugging loved ones," said Anja Krammer, President, BioPharmX. "We're excited to finally bring to market a product in Violet iodine that will help the millions of women whose breast discomfort has interfered with their daily lives for far too long."*

Violet iodine is now available for sale online without a prescription in 30 and 60 count packages and can be found in the feminine care aisle of major retailers beginning 2015.

About Violet™ Iodine
Violet iodine is a daily iodine supplement for the relief of the most common symptoms of cyclic mastalgia and fibrocystic breast condition (FBC), including monthly swelling, tenderness, aches and heaviness. Violet iodine is available in 30 and 60 count packages at Walgreen Co.'s (NYSE: WAG) (NASDAQ: WAG) drugstore.com™ web store. To learn more about Violet iodine, visit www.VioletDaily.com.

About Fibrocystic Breast Condition (FBC)

Fibrocystic breast condition (FBC) is the generally accepted term to describe common, benign breast discomfort caused by the influx of hormones during the menstrual cycle. FBC, which affects an estimated 50 percent of women ages 15 to 49,1 can cause monthly breast tenderness, aches, swelling, and heaviness. In women with FBC, the hormones estrogen and prolactin cause breast cells to build up month over month with each menstrual cycle, causing swollen breast tissue that can develop into lumps and masses. While a benign condition, FBC can impact many aspects of a woman's life, including intimacy, clothing selection and exercise.

About BioPharmX Corporation
BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based biotechnology company, which seeks to provide innovative products through unique, proprietary platform technologies for prescription, over-the-counter ("OTC"), and supplement applications in the fast-growing health and wellness markets, including women's health, dermatology, and otolaryngology (ears, nose & throat). To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statements
Statements in this news release relating to the business of BioPharmX, which are not historical facts, are "forward-looking statements." These forward-looking statements may be identified by words such as "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company's filings with the Securities and Exchange Commission (SEC). Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Violet is a trademark of BioPharmX Inc.

*These statements have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Contact:

Nina Brauer

BioPharmX Media Relations                         

Tel: 650-889-5030

Email: [email protected]

Kim Angelastro

Cohn & Wolfe, on behalf of BioPharmX

Tel: 212-798-9740

Email: [email protected]

1 JH Kessler, "The Effect of Supraphysiologic Levels of Iodine on Patients with Cyclic Mastalgia" The Breast Journal, 2004; 10(4) 328–336. Note: The Kessler study did not include selenium and included sodium iodide and sodium iodate instead of potassium iodide and potassium iodate.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/7378951-biopharmx-introducing-violet-iodine-premenstrual-breast-discomfort

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/introducing-violet-iodine-new-once-daily-non-prescription-pill-for-relief-of-premenstrual-breast-discomfort-300006880.html

SOURCE BioPharmX Corporation

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.